Toward an integrated human clearance prediction strategy that minimizes animal use

Journal of Pharmaceutical Sciences

Volumn 100, Issue 10, 2011, Pages 4518-4535

  Beaumont, Kevin ^a   Gardner, Iain ^a   Chapman, Kathryn ^b   Hall, Michael ^c   Rowland, Malcolm ^d  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b National Centre for the Replacement   (United Kingdom)

^c HUNTINGDON LIFE SCIENCES   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Clearance; Clinical pharmacokinetics; Cytochrome P450; In vitro in vivo correlations (IVIVC); Renal clearance

Indexed keywords

ALFENTANIL; ALPRAZOLAM; AMITRIPTYLINE; AMLODIPINE; BUSPIRONE; CHLORPROMAZINE; CITALOPRAM; DIAZEPAM; DICLOFENAC; DILTIAZEM; DIPHENHYDRAMINE; DOXEPIN; ELETRIPTAN; ERYTHROMYCIN; FELODIPINE; HALOPERIDOL; INDINAVIR; LIDOCAINE; MELOXICAM; METOPROLOL; MIDAZOLAM; NICARDIPINE; NIMODIPINE; ONDANSETRON; PHENAZONE; PHENCYCLIDINE; PHENYTOIN; PRAZOSIN; QUINIDINE; UNINDEXED DRUG; CYTOCHROME P450; DRUG; ISOENZYME;

ALLOMETRY; ANIMAL USE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG EXCRETION; DRUG METABOLISM; HUMAN; IN VITRO STUDY; KIDNEY CLEARANCE; LIVER MICROSOME; NONHUMAN; PREDICTIVE VALUE; RAT; SINGLE SPECIES SCALING; URINARY EXCRETION; ANIMAL; ANIMAL TESTING ALTERNATIVE; BILIARY EXCRETION; BIOLOGICAL MODEL; BIOTRANSFORMATION; COMPARATIVE STUDY; ENZYMOLOGY; METABOLISM; PRIMATE; REPRODUCIBILITY; SPECIES DIFFERENCE;

ANIMAL TESTING ALTERNATIVES; ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOBILIARY ELIMINATION; HUMANS; ISOENZYMES; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PRIMATES; RATS; RENAL ELIMINATION; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY;

EID: 80052268766     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22635     Document Type: Article

References (39)

1. Kennedy T. 1997. Managing the drug discovery/development interface. Drug Discov Today 2(10):436-444.
2. Prentis RA, Lis Y, Walker SR. 1988. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 25(3):387-396.
3. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711-715.
4. Beaumont K, Smith DA. 2009. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? Curr Opin Drug Discov Devel 12(1):61-71.
5. Evans CA, Jolivette LJ, Nagilla R, Ward KW. 2006. Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. Drug Metab Dispos 34(7):1255-1265.
6. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K. 2009. Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49(5):513-533.
7. Jolivette LJ, Ward KW. 2005. Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. J Pharm Sci 94(7):1467-1483.
8. Mahmood I. 2007. Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 59(11):1177-1192.
9. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283(1):46-58.
10. Tang H, Mayersohn M. 2006. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 95(8):1783-1799.
11. Ward KW, Coon DJ, Magiera D, Bhadresa S, Nisbett E, Lawrence MS. 2008. Exploration of the African green monkey as a preclinical pharmacokinetic model: Intravenous pharmacokinetic parameters. Drug Metab Dispos 36(4):715-720.
12. Ward KW, Nagilla R, Jolivette LJ. 2005. Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. Xenobiotica 35(2):191-210.
13. Ward KW, Smith BR. 2004. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 32(6):603-611.
14. Houston JB. 1994. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47(9):1469-1479.
15. Ito K, Houston JB. 2005. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22(1):103-112.
16. Lave T, Chapman K, Goldsmith P, Rowland M. 2009. Human clearance prediction: Shifting the paradigm. Expert Opin Drug Metab Toxicol 5(9):1039-1048.
17. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27(11):1350-1359.
18. Riley RJ, McGinnity DF, Austin RP. 2005. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33(9):1304-1311.
19. Stringer R, Nicklin PL, Houston JB. 2008. Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. Xenobiotica 38(10):1313-1329.
20. Nagilla R, Frank KA, Jolivette LJ, Ward KW. 2006. Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance. J Pharmacol Toxicol Methods 53(2):106-116.
21. Hallifax D, Foster JA, Houston JB. 2010. Prediction of human metabolic clearance from in vitro systems: Retrospective analysis and prospective view. Pharm Res 27(10):2150-2161.
22. Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. 2006. Prediction of metabolic drug clearance in humans: In vitro-in vivo extrapolation vs allometric scaling. Xenobiotica 36(7):567-580.
23. Obach RS, Lombardo F, Waters NJ. 2008. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36(7):1385-1405.
24. Mahmood I, Sahajwalla C. 1999. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 36(4):277-287.
25. Pang KS, Rowland M. 1977. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5(6):625-653.
26. Chiou WL, Robbie G, Chung SM, Wu TC, Ma C. 1998. Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: Mean allometric coefficient of 0.66. Pharm Res 15(9):1474-1479.
27. Tang H, Hussain A, Leal M, Mayersohn M, Fluhler E. 2007. Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35(10):1886-1893.
28. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. 2004. Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32(11):1201-1208.
29. Tang H, Mayersohn M. 2006. On the observed large interspecies overprediction of human clearance ("vertical allometry") of UCN-01: Further support for a proposed model based on plasma protein binding. J Clin Pharmacol 46(4):398-400.
30. Korfmacher WA, Veals J, Dunn-Meynell K, Zhang X, Tucker G, Cox KA, Lin CC. 1999. Demonstration of the capabilities of a parallel high-performance liquid chromatography tandem mass spectrometry system for use in the analysis of drug discovery plasma samples. Rapid Commun Mass Spectrom 13(20):1991-1998.
31. Caldwell GW, Masucci JA, Yan Z, Hageman W. 2004. Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted from in-vivo rat data? Eur J Drug Metab Pharmacokinet 29(2):133-143.
32. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093-1095.
33. Goteti K, Brassil PJ, Good SS, Garner CE. 2008. Estimation of human drug clearance using multiexponential techniques. J Clin Pharmacol 48(10):1226-1236.
34. Mahmood I. 2009. Application of fixed exponent 0. 75 to the prediction of human drug clearance: An inaccurate and misleading concept. Drug Metabol Drug Interact 24(1):57-81.
35. Mahmood I. 2009. Role of fixed coefficients and exponents in the prediction of human drug clearance: How accurate are the predictions from one or two species? J Pharm Sci 98(7):2472-2493.
36. Tang H, Hussain A, Leal M, Fluhler E, Mayersohn M. 2011. Controversy in the allometric application of fixed-versus varying-exponent models: A statistical and mathematical perspective. J Pharm Sci 100(2):402-410.
37. Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22(1):11-23.
38. Luo G, Johnson S, Hsueh MM, Zheng J, Cai H, Xin B, Chong S, He K, Harper TW. 2010. In silico prediction of biliary excretion of drugs in rats based on physicochemical properties. Drug Metab Dispos 38(3):422-430.
39. Lappin G, Wagner CC, Langer O, van de Merbel N. 2009. New ultrasensitive detection technologies and techniques for use in microdosing studies. Bioanalysis 1(2):357-366.